Free Trial

Omega Therapeutics Q4 2023 Earnings Report

Omega Therapeutics logo
$0.55 -0.02 (-3.04%)
As of 01/17/2025 04:00 PM Eastern

Omega Therapeutics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.46
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Omega Therapeutics Revenue Results

Actual Revenue
$0.99 million
Expected Revenue
$0.93 million
Beat/Miss
Beat by +$60.00 thousand
YoY Revenue Growth
N/A

Omega Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Omega Therapeutics Earnings Headlines

Omega Therapeutics Chair Resigns from Board of Directors
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Omega Therapeutics Reports Third Quarter 2024 Results
Omega Therapeutics price target lowered to $4 from $9 at Piper Sandler
Piper Sandler Remains a Buy on Omega Therapeutics (OMGA)
See More Omega Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Omega Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omega Therapeutics and other key companies, straight to your email.

About Omega Therapeutics

Omega Therapeutics (NASDAQ:OMGA) operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

View Omega Therapeutics Profile

More Earnings Resources from MarketBeat